Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiotricityBTCY -4.55%21 EV-to-EBITDA is 17.99 as of Aug. 09, 2026. GuruFocus rates BTCY with a GF Score™ of 21/100 and a GF Value™ of $0.38 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 512 Medical Devices & Instruments companies, Biotricity ranks worse than 60.55% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Biotricity's enterprise value is $30.75 Mil.
Biotricity's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $1.71 Mil. Therefore, Biotricity's EV-to-EBITDA for today is 17.99.
The historical rank and industry rank for Biotricity's EV-to-EBITDA or its related term are showing as below:
BTCY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.47 Med: -3.77 Max: 343.92
Current: 17.99
During the past 13 years, the highest EV-to-EBITDA of Biotricity was 343.92. The lowest was -173.47. And the median was -3.77.
BTCY's EV-to-EBITDA is ranked worse than 60.55% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.645
vs BTCY: 17.99
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Biotricity's share price for today is $0.105.
Biotricity's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.116.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Biotricity's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Biotricity's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biotricity EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Biotricity's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Biotricity's EV-to-EBITDA falls into.
Biotricity's current Enterprise Value is $30.75 Mil.
Biotricity's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biotricity (BTCY) has a EV-to-EBITDA of 17.99 as of Aug. 09, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biotricity. According to the industry distribution chart, Biotricity ranks #310 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 60.5%.
Is Biotricity's EV-to-EBITDA too high?
Biotricity's current EV-to-EBITDA is 17.99. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.65. Biotricity's value of 17.99 is 22.8% above this industry median. Based on the distribution chart, Biotricity ranks #310 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Biotricity has a GF Score™ of 21/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Biotricity's EV-to-EBITDA compare to VYCO and FEED?
According to the Medical Devices & Instruments industry distribution chart, Biotricity ranks #310 out of 512 companies for EV-to-EBITDA. This places Biotricity in the lower half of its industry. The industry median EV-to-EBITDA is 14.65. Biotricity's value of 17.99 is 22.8% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.65, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biotricity's current EV-to-EBITDA of 17.99 is 22.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Biotricity. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biotricity's current EV-to-EBITDA is 17.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotricity stock overvalued right now?
Based on GuruFocus' analysis, Biotricity (BTCY) is currently considered Possible Value Trap. The stock's GF Value™ is $0.38, compared to a current price of $0.11 — trading 72.4% below its estimated fair value. The current EV-to-EBITDA is 17.99 and 22.8% above the Medical Devices & Instruments industry median of 14.65. Biotricity's overall GF Score™ is 21/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Biotricity (BTCY), the current EV-to-EBITDA is 17.99 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biotricity (BTCY) Overvalued in 2026?
Based on GuruFocus' analysis, Biotricity stock appears to be undervalued.
The current stock price of $0.11 is trading 72.4% below its estimated GF Value™ of $0.38.
GuruFocus considers Biotricity to be Possible Value Trap.
Key valuation signals for BTCY:
EV-to-EBITDA: 17.99
GF Value™: $0.38 vs. price of $0.11 (72.4% below fair value)
Industry Position: 22.8% above the Medical Devices & Instruments median (#310 of 512)
No single metric tells the full story. See the BTCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biotricity Inc is a medical technology company that focuses on biometric data monitoring solutions. It aims to deliver remote monitoring solutions to the healthcare & consumer markets, with a focus on diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. Biotricity is expanding medical-grade monitoring into the consumer market via its Biolife solution, which empowers users to self-manage chronic conditions. Its products include Bioflux, which is a mobile cardiac telemetry (MCT) device that provides real-time monitoring and transmission of ambulatory patients' ECG information; Biocare Telemed; Bioheart, which is a personal heart monitor; Biokit, and Biocare health.
21GF Score
Get the complete analysis for BTCY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BTCY has been successfully added to your 
